查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976736

周邊動脈疾病治療市場：按產品類型、適應症、給藥途徑和最終用戶分類 - 全球預測 2026-2032 年

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，周邊動脈疾病治療市場價值將達到 56 億美元，到 2026 年將成長至 61.1 億美元，到 2032 年將達到 103 億美元，複合年成長率為 9.08%。

主要市場統計數據
基準年 2025 56億美元
預計年份：2026年 61.1億美元
預測年份 2032 103億美元
複合年成長率 (%) 9.08%

全面概述周邊動脈疾病的治療方法，並從臨床、營運和商業性因素的角度出發，探討影響治療路徑和相關人員決策的因素。

周邊動脈疾病處於血管病理學、治療方法創新和不斷發展的醫療服務模式的複雜交匯點。本執行摘要整合了多學科證據，重點闡述了臨床實務、法規環境和商業策略之間的交集。以下說明將著重於從傳統藥物療法到器械介入治療的治療方法，並結合醫療系統優先事項和以患者為中心的治療結果，探討這些進展。

程序創新、藥物進步和數位化照護路徑如何共同重新定義周邊動脈疾病。

臨床實務與科技的融合正在改變周邊動脈疾病的診斷、治療和管理。近年來，在影像技術、導管技術和輔助器械進步的支持下，微創血管內治療技術發展迅速。伴隨這些手術技術的進步，人們重新關注藥物治療策略，不再僅限於緩解症狀，而是致力於降低重大心血管事件的發生率，這促使整個醫學領域重新建構治療目標。

根據 2025 年美國關稅變化對治療生態系統成本動態和營運連續性的影響，我們預測供應鏈調整、籌資策略和產品設計將會改變。

美國預計2025年的關稅政策變化可能會影響周邊動脈疾病治療生態系統的多個環節，相關人員已開始為各種連鎖反應做好準備。對進口醫療設備、藥品和中間組件徵收關稅可能會增加專用導管、藥物釋放型球囊和診斷成像設備等設備的到岸成本。因此，製造商和醫療系統可能會調整籌資策略，並尋求透過使用替代供應商、近岸外包或加速生產本地化來降低風險。

整合產品子類別、臨床適應症、醫療保健服務管道和給藥途徑的策略性細分洞察，對於指導開發和商業化選擇至關重要。

深入了解患者族群特徵、產品和通路對於將研發與商業化策略結合至關重要。所考慮的產品類型包括抗凝血劑、抗血小板藥物、溶栓劑和血管擴張劑。抗凝血劑又可細分為直介面服抗凝血劑 (DOAC)、肝素和Warfarin；抗血小板藥物包括阿斯匹靈、Clopidogrel和替格瑞洛；溶栓劑包括組織型胞漿素原原活化劑 (t-PA) 和尿激酶；血管擴張劑通常為Cilostazol和Pentoxifylline。這些差異會影響臨床決策、處方集選擇和術後管理，因為每個亞類都有其獨特的動態、監測要求和交互作用特徵。

美洲、歐洲、中東和非洲以及亞太地區的區域特徵和戰略意義決定了監管方法、證據需求和准入策略。

區域趨勢對臨床實踐、監管預期和供應鏈結構有著深遠的影響。在美洲，臨床指引日益強調在關注肢體介入的同時，也要注重綜合性的心血管風險降低，而醫療系統則需要在專科醫生數量和不斷成長的門診量之間尋求平衡。該地區的支付模式也存在顯著差異，這會影響新治療方法的可及性和處方集時間。因此，優先創建真實世界證據和以支付方為中心的衛生經濟學數據的策略，很可能在商業性談判中獲得支持。

如何透過夥伴關係、擴展終點和製造彈性將製藥、醫療設備和數位解決方案策略融合起來，從而創造臨床和商業性價值。

在周邊動脈疾病治療領域，各公司正採取多元化的策略，涵蓋漸進式創新、平台開發和策略聯盟。生物製藥公司專注於研發差異化分子和具有複雜心血管獲益特徵的藥物，以改善肢體功能並降低全身動脈粥狀硬化風險。同時，醫療設備製造商正投資於新型塗層、導管設計和複合材料產品，以輔助藥物治療方案，並專注於提升手術效率、藥物傳遞和耐用性。

產業領導者可採取切實可行的策略重點，加強供應鏈，擴大證據生成，整合數位醫療，以加速治療方法的採用和支付方的接受。

產業領導者必須採取果斷行動，將科學進步和營運轉型轉化為永續的競爭優勢。首先，各機構應加快建構跨學科證據，將手術創新與心血管和肢體長期療效聯繫起來，從而增強其對支付方和醫療保健系統的價值提案。其次，價值鏈多元化和區域化生產模式可以降低關稅波動風險，並提高對臨床醫生需求的應對力。投資模組化設備設計並從多個地區採購關鍵部件可以增強營運韌性。

採用方法嚴謹的調查方法，結合臨床醫師訪談、臨床文獻、監管分析和情境規劃，以檢驗策略見解和建議。

本研究整合了一級資訊來源和二級資訊來源，對周邊動脈疾病治療領域進行了穩健且可重複的評估。一手調查包括對臨床醫生、醫院採購經理、門診手術中心管理人員和臨床試驗研究人員進行結構化訪談，以收集有關藥物治療方案和器械使用流程的實際資訊。這些定性研究結果輔以對公開臨床試驗註冊資訊、同儕審查文獻、監管指導文件和醫療技術評估的分析，以確保臨床和監管方面的嚴謹性。

綜合考慮臨床進展、供應鏈壓力和戰略需求，我們確定了周邊動脈疾病相關人員的短期優先事項。

周邊動脈疾病的治療涉及三大要素：不斷發展的臨床科學、不斷變化的醫療保健格局以及複雜的商業性壓力。該領域的特點是血管內治療技術取得了顯著進步，人們重新關注能夠降低全身風險的抗血栓策略，並且越來越需要能夠證明肢體持續保全和患者功能改善的證據。這些發展是在各地法規不盡相同以及關稅可能導致供應鏈中斷的背景下進行的，因此需要製造商和醫療服務提供者採取積極主動、全面的策略應對措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章周邊動脈疾病治療市場：依產品類型分類

  • 抗凝血劑
    • 口服直接抗凝血劑
    • 肝素
    • Warfarin
  • 抗血小板藥物
    • 阿斯匹靈
    • Clopidogrel
    • 奇卡格雷洛
  • 溶栓劑
    • 組織型胞漿素原原活化劑
    • 尿激酶
  • 血管擴張劑
    • Cilostazol
    • Pentoxifylline

第9章周邊動脈疾病治療市場：依適應症分類

  • 嚴重下肢缺血
  • 間歇性跛行

第10章周邊動脈疾病治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外

第11章周邊動脈疾病治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章周邊動脈疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章周邊動脈疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章周邊動脈疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國周邊動脈疾病治療市場

第16章：中國周邊動脈疾病治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alucent Biomedical Inc.
  • AnGes, Inc.
  • AngioDynamics, Inc.
  • ARCA biopharma, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Helixmith Co., Ltd.
  • Koninklijke Philips NV
  • LeMaitre Vascular, Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • REVA Medical, LLC
  • Terumo Corporation
  • Venturis Therapeutics, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market was valued at USD 5.60 billion in 2025 and is projected to grow to USD 6.11 billion in 2026, with a CAGR of 9.08%, reaching USD 10.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.60 billion
Estimated Year [2026] USD 6.11 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 9.08%

An integrated overview of peripheral arterial disease therapeutics that frames clinical, operational, and commercial drivers shaping treatment pathways and stakeholder decisions

Peripheral arterial disease represents a complex intersection of vascular pathology, therapeutic innovation, and shifting care delivery models. This executive summary synthesizes multidisciplinary evidence to illuminate where clinical practice, regulatory environments, and commercial strategy converge. The narrative that follows focuses on therapeutic modalities ranging from classical pharmacotherapies to device-based interventions, and frames these developments against the backdrop of health system priorities and patient-centric outcomes.

The clinical burden of limb ischemia and intermittent claudication continues to drive demand for both established agents and next-generation therapeutics. Consequently, clinicians and payers increasingly evaluate interventions on procedural efficacy, long-term limb salvage, and cardiovascular risk reduction. Moreover, the patient journey now commonly involves outpatient pathways, integrated wound care, and coordinated vascular teams that emphasize functional recovery alongside survival metrics. Given these realities, stakeholders must integrate clinical evidence with operational feasibility and evolving reimbursement paradigms to optimize therapeutic adoption and patient outcomes.

How procedural innovation, pharmacologic evolution, and digital care pathways are jointly redefining standards of treatment and long-term management for peripheral arterial disease

Clinical practice and technology are converging to create transformative shifts in how peripheral arterial disease is diagnosed, treated, and managed. In recent years, minimally invasive endovascular techniques have advanced rapidly, supported by improvements in imaging, catheter technologies, and adjunctive devices. These procedural advances have coincided with a renewed focus on pharmacologic strategies that extend beyond symptom relief to reduce major adverse cardiovascular events, thereby reframing therapeutic objectives across care settings.

Concurrently, digital health and remote monitoring are changing post-procedural follow-up and chronic disease management. Telemedicine-facilitated vascular clinics and wearable-enabled gait and perfusion monitoring complement traditional vascular labs, enabling earlier detection of deterioration and tailored rehabilitation programs. At the same time, regenerative medicine and targeted biologics continue to progress through clinical development, promising alternative pathways for patients with limited revascularization options. Finally, care delivery has shifted toward ambulatory settings for selected procedures, increasing the strategic importance of ambulatory surgical centers and specialty clinics as sites of care. Together, these factors are driving integrated care models that prioritize value, patient experience, and longitudinal outcomes.

Anticipating supply chain adjustments, procurement strategies, and product design shifts as U S tariff changes in 2025 reshape cost dynamics and operational resilience in the therapeutic ecosystem

Changes in U.S. tariff policy projected for 2025 have the potential to affect multiple elements of the peripheral arterial disease therapeutic ecosystem, and stakeholders are already preparing for varied ripple effects. Tariffs on imported medical devices, pharmaceuticals, and intermediate components may increase landed costs for devices such as specialized catheters, drug-coated balloons, and diagnostic imaging equipment. As a result, manufacturers and health systems may reassess sourcing strategies, seeking to mitigate exposure through alternative suppliers, nearshoring, or accelerated localization of production.

Moreover, tariffs can influence the supply chain timing and inventory strategies adopted by hospitals and ambulatory surgical centers. In the near term, purchasing teams may expand buffer inventories or renegotiate supply contracts to stabilize access to critical consumables. Over time, manufacturers could revise pricing models or shift manufacturing footprints, which in turn would affect procurement cycles and capital planning for facility upgrades. From a research and development perspective, tariff-driven cost pressures may reorient investment priorities toward cost-efficient innovations and modular device designs that rely less on tariff-exposed components. Finally, regulatory and payer responses may evolve to address affordability and access, prompting collaborative initiatives to preserve continuity of care without compromising clinical standards.

Strategic segmentation insights that integrate product subclasses, clinical indications, care delivery channels, and administration routes to inform development and commercialization choices

A granular understanding of patient, product, and channel segmentation is essential to align research, development, and commercialization strategies. Product type considerations span anticoagulants, antiplatelet agents, thrombolytics, and vasodilators, with anticoagulants subdividing into direct oral anticoagulants, heparin, and warfarin while antiplatelet agents encompass aspirin, clopidogrel, and ticagrelor; thrombolytics include tissue plasminogen activator and urokinase, and vasodilators are typified by cilostazol and pentoxifylline. These distinctions influence clinical decision-making, formulary placement, and post-procedural management, since each subclass carries unique pharmacodynamics, monitoring requirements, and interaction profiles.

Indication-based segmentation discriminates between critical limb ischemia and intermittent claudication, which differ markedly in disease trajectory, therapeutic urgency, and multidisciplinary care needs. End-user channels range from ambulatory surgical centers to hospitals and specialty clinics, and the choice of setting impacts device selection, staffing models, reimbursement pathways, and length of stay. Finally, route of administration - oral versus parenteral - intersects with adherence considerations, outpatient feasibility, and resource allocation for monitoring and administration. By integrating these segmentation axes, stakeholders can prioritize clinical development programs, tailor marketing messages, and design access strategies that address the nuanced needs of clinicians, payers, and patients.

Regional contours and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate regulatory approaches, evidence needs, and access strategies

Regional dynamics exert a powerful influence on clinical practice, regulatory expectations, and supply chain architecture. In the Americas, clinical guidelines increasingly emphasize integrated cardiovascular risk reduction alongside limb-focused interventions, while health systems balance specialist capacity with growing outpatient procedural volumes. This region also exhibits significant heterogeneity in payer models, which affects formulary access and adoption timelines for novel therapies. Consequently, strategies that prioritize real-world evidence generation and payer-centric health economic dossiers will find traction in commercial conversations.

Across Europe, Middle East & Africa, regulatory harmonization and varying reimbursement pathways shape market entry strategies and clinical adoption rates. In many markets, authorities place a premium on long-term outcomes and cost-effectiveness data, which can lengthen time to wide adoption but also create durable value propositions for therapies that demonstrate limb salvage and cardiovascular benefit. In contrast, Asia-Pacific markets are characterized by rapid uptake of minimally invasive procedures, expanding interventional capacity, and strong domestic manufacturing ambitions, which together influence pricing dynamics and partnership models. Recognizing these regional contours allows sponsors to sequence market entry, localize evidence generation, and optimize manufacturing footprints to meet distinct regulatory and commercial requirements.

How pharmaceutical, medical device, and digital solution strategies are converging through partnerships, expanded endpoints, and manufacturing resilience to capture clinical and commercial value

Companies operating in the peripheral arterial disease therapeutic space are pursuing diversified strategies that span incremental innovation, platform development, and strategic partnerships. Biopharmaceutical firms emphasize differentiated molecules and composite cardiovascular benefit profiles that address both limb outcomes and systemic atherosclerotic risk. At the same time, medical device manufacturers focus on procedural efficiency, deliverability, and durability, investing in novel coatings, catheter design, and combination products that complement pharmacologic regimens.

Across the industry, collaboration between pharma and device players is increasingly common, enabling bundled value propositions that align procedural and medical management. Additionally, growing interest in digital therapeutics and remote monitoring has catalyzed partnerships with software and analytics providers to enhance post-procedural care and patient engagement. From a corporate strategy perspective, companies are prioritizing regulatory alignment early in development, expanding clinical endpoints to include functional and quality-of-life measures, and pursuing manufacturing resilience to mitigate tariff and supply chain risks. These approaches collectively reflect a shift toward holistic solutions that extend beyond single-modality interventions.

Actionable strategic priorities for industry leaders to fortify supply chains, amplify evidence generation, and integrate digital care to accelerate therapy adoption and payer acceptance

Industry leaders must act decisively to convert scientific advances and operational shifts into sustainable competitive advantage. First, organizations should accelerate cross-disciplinary evidence generation that links procedural innovation with long-term cardiovascular and limb outcomes, thereby strengthening value propositions for payers and health systems. Secondly, supply chain diversification and regional manufacturing options will reduce exposure to tariff volatility and improve responsiveness to clinician demand. Investing in modular device designs and procuring critical components from multiple geographies will enhance operational resilience.

Furthermore, companies should integrate digital health solutions to support adherence, remote monitoring, and rehabilitation pathways that improve functional recovery and reduce readmissions. Engaging regulators and payers early, and designing trials that incorporate patient-reported outcomes and health economic endpoints, will facilitate reimbursement readiness. Finally, targeted commercial strategies that reflect segmentation across product subtypes, indications, care settings, and routes of administration will maximize uptake; aligning sales and clinical education programs to ambulatory surgical center workflows and hospital procurement practices will accelerate diffusion of novel therapies.

A methodologically rigorous approach combining clinician interviews, clinical literature, regulatory analysis, and scenario planning to validate strategic insights and recommendations

This research synthesizes primary and secondary sources to deliver a robust, reproducible assessment of the peripheral arterial disease therapeutics landscape. Primary research included structured interviews with clinicians, hospital procurement leaders, ambulatory surgical center administrators, and clinical trial investigators to capture frontline experiences with pharmacologic regimens and device workflows. These qualitative insights were supplemented with analyses of publicly available clinical trial registries, peer-reviewed literature, regulatory guidance documents, and health technology assessments to ensure clinical and regulatory rigor.

The analytical framework incorporates a multi-axis segmentation approach, scenario planning for supply chain and tariff exposures, and thematic triangulation across clinical outcomes, payer requirements, and commercial pathways. Data validation processes involved cross-referencing interview findings with published procedure utilization trends and device approval histories. Finally, sensitivity checks and expert reviews helped refine strategic implications and recommendations, ensuring the report supports decision-makers seeking evidence-based pathways for development, commercialization, and operations within this evolving therapeutic area.

Synthesis of clinical advances, supply chain pressures, and strategic imperatives that together define the near-term priorities for peripheral arterial disease stakeholders

Peripheral arterial disease therapeutics sits at the intersection of evolving clinical science, changing care settings, and complex commercial pressures. The landscape is characterized by meaningful advances in endovascular technology, renewed emphasis on antithrombotic strategies that reduce systemic risk, and increasing demand for evidence that demonstrates durable limb salvage and improved patient function. These developments occur against a backdrop of regional regulatory diversity and potential tariff-driven supply chain disruptions, which together require proactive and integrated strategic responses from manufacturers and providers.

In sum, stakeholders that align product development with payer evidence needs, invest in supply chain agility, and leverage digital care to enhance outcomes will be best positioned to navigate the coming years. By prioritizing multidisciplinary evidence generation and adaptive commercialization models, organizations can translate scientific innovation into sustained clinical benefit and commercial viability. The result will be a more resilient, patient-centered therapeutic ecosystem for individuals living with peripheral arterial disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Arterial Disease Therapeutics Market, by Product Type

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
    • 8.1.2. Heparin
    • 8.1.3. Warfarin
  • 8.2. Antiplatelet Agents
    • 8.2.1. Aspirin
    • 8.2.2. Clopidogrel
    • 8.2.3. Ticagrelor
  • 8.3. Thrombolytics
    • 8.3.1. Tissue Plasminogen Activator
    • 8.3.2. Urokinase
  • 8.4. Vasodilators
    • 8.4.1. Cilostazol
    • 8.4.2. Pentoxifylline

9. Peripheral Arterial Disease Therapeutics Market, by Indication

  • 9.1. Critical Limb Ischemia
  • 9.2. Intermittent Claudication

10. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Peripheral Arterial Disease Therapeutics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Peripheral Arterial Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peripheral Arterial Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peripheral Arterial Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Peripheral Arterial Disease Therapeutics Market

16. China Peripheral Arterial Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alucent Biomedical Inc.
  • 17.7. AnGes, Inc.
  • 17.8. AngioDynamics, Inc.
  • 17.9. ARCA biopharma, Inc.
  • 17.10. B. Braun SE
  • 17.11. Becton, Dickinson and Company
  • 17.12. BIOTRONIK SE & Co. KG
  • 17.13. Boston Scientific Corporation
  • 17.14. Cook Group Incorporated
  • 17.15. Helixmith Co., Ltd.
  • 17.16. Koninklijke Philips N.V.
  • 17.17. LeMaitre Vascular, Inc.
  • 17.18. Medtronic PLC
  • 17.19. Meril Life Sciences Pvt. Ltd.
  • 17.20. MicroPort Scientific Corporation
  • 17.21. REVA Medical, LLC
  • 17.22. Terumo Corporation
  • 17.23. Venturis Therapeutics, Inc.
  • 17.24. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)